Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Funding sources: None.
| Conflicts of interest: This was an investigator-initiated trial. The drug adalimumab biosimilar (Exemptia) was provided by Zydus Biovation (division of Cadila Health Care) free of cost to all patients. Zydus Biovation had no interference in the design, conduct, and analysis of the study.
| IRB approval status: Reviewed and approved by All India Institute of Medical Sciences Ethics Committee, New Delhi (approval reference number IEC-83/08.01.2016, RP-11/2016).